Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects
FDOCT
+ Dynamic Vessel Analyzer
+ FDOCT
Autoimmune Diseases+5
+ Diabetes Mellitus
+ Endocrine System Diseases
Basic Science Study
Summary
Study start date: January 12, 2015
Actual date on which the first participant was enrolled.The prevalence of diabetes and diabetes-associated complications is still increasing. Several major long-term complications of diabetes such as cardiovascular disease, chronic renal failure, diabetic retinopathy and others relate to the damage of blood vessels. Given that the eye provides the unique possibility in the human body to directly visualize blood vessels, much interest has been directed towards studying the ocular circulation. Although data of large epidemiological studies indicate that changes in retinal vessel caliber reflect other diabetes related factors, such as fasting glucose levels, there is still conflicting evidence on blood flow alterations in patients with diabetes. This is also related to the fact that up to now, methodological difficulties aggravate the assessment of blood flow changes in the retina in larger groups of patients. In the present study we propose to overcome this problem by using a technique called bi-directional Fourier Domain Doppler Optical Coherence Tomography (FDOCT), which we have developed in the recent years to measure retinal blood velocities. This technique allows for the non-invasive investigation of blood flow changes in human retina and will help us to better understand diabetes related vascular changes. The present study will use this technique to assess retinal blood flow changes in patients with diabetes and healthy subjects.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.48 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Basic Science Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Inclusion criteria for healthy subjects Men and women aged over 18 years Non-smokers Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant Normal ophthalmic findings, ametropia < 6 Dpt. Inclusion criteria for patients with diabetes Men and women aged over 18 years Non-smokers Previously diagnosed type I diabetes No or mild non-proliferative diabetic retinopathy Normal ophthalmic findings except mild diabetic retinopathy, ametropia < 6 Dpt. Exclusion Criteria: Any of the following will exclude a healthy subject from the study: Symptoms of a clinically relevant illness in the 3 weeks before the first study day Presence or history of a severe medical condition as judged by the clinical investigator Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study (except oral contraceptive) Arterial hypertension (defined as either systolic blood pressure >145 mmHg or diastolic blood pressure >90 mmHg) Blood donation during the previous three weeks Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator Best corrected visual acuity < 0.8 Snellen Ametropia >= 6 Dpt Pregnancy, planned pregnancy or lactating Any of the following will exclude a patient with diabetes from the study: Participation in a clinical trial in the 3 weeks preceding the screening visit Symptoms of a clinically relevant illness in the 3 weeks before the first study day Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator Arterial hypertension (defined as either systolic blood pressure >145 mmHg or diastolic blood pressure >90 mmHg) Blood donation during the previous three weeks Moderate to severe non-proliferative or proliferative diabetic retinopathy Previous laser photocoagulation treatment Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator Best corrected visual acuity < 0.8 Snellen Ametropia >= 6 Dpt Pregnancy, planned pregnancy or lactating
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Group II
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Department of Clinical Pharmacology
Vienna, AustriaOpen Department of Clinical Pharmacology in Google Maps